Researchers have made a groundbreaking advance in cancer treatment by successfully using Seraph® 100 blood filtration media to remove Circulating Tumor Cells (CTCs) from patients with advanced pancreatic cancer. This breakthrough supports ExThera Medical’s ONCObind™ Procedure Hemoperfusion Filter (ONCObind™), designed to enhance longevity and outcomes by reducing or eliminating cancer metastasis. By utilizing Seraph® 100, ONCObind™ effectively filters CTCs from the bloodstream.
“This device offers a significant opportunity to enhance care for pancreatic cancer patients and potentially benefit other cancer types.”
Metastasis is a key factor in the lethality of many cancers, with CTCs playing a crucial role in this process. Removing these cells through ONCObind™ presents a promising strategy to interrupt metastasis and improve patient survival.
Studies demonstrate substantial reduction in CTCs using the hemoperfusion media in patient blood samples. Researchers suggest that blood purification with Seraph® 100 may offer a novel therapy for pancreatic ductal adenocarcinoma (PDAC), either independently or in conjunction with existing treatments. They also propose that these findings could establish treatment protocols for other cancers by reducing metastatic potential and enhancing survival rates.
Dr. Peter Kuhn, PhD, lead researcher and Founding Director of the USC Michelson Convergent Science Institute of Cancer, emphasized, “By removing CTCs, we may disrupt the metastatic process and improve patient outcomes. This device offers a significant opportunity to enhance care for pancreatic cancer patients and potentially benefit other cancer types.”
In vitro blood filtration using Seraph® 100 was conducted on blood samples from PDAC patients in the study, revealing significant reductions in CTCs. This oncology-focused product could serve as a therapeutic tool alone or alongside traditional treatments like chemotherapy and radiation.
Erin Borger, CEO of ExThera Medical, highlighted the device’s potential, noting an average 94% reduction in circulating tumor cells with single-use technology. The company remains committed to further research to gauge its impact on patient care.
The study results were published in Nature’s BJC Reports.
About ExThera Medical Corporation
ExThera Medical Corporation specializes in extracorporeal blood filtration devices, including the Seraph® 100 MicroBind® Affinity Blood Filter, designed to remove a wide array of pathogens from patients’ bloodstreams. Seraph® 100 is utilized in various healthcare settings to combat infections caused by hospital-acquired pathogens, battlefield injuries, pandemics, and biological warfare agents. ExThera Medical’s products have proven lifesaving in critically ill patients suffering from sepsis, COVID-19, and severe bloodstream infections. With extensive clinical data and regulatory approvals, including CE Mark and FDA Emergency Use Authorization, Seraph® 100 is available globally to address critical healthcare needs.
